Addington J, Shalev A, Liu L, Jahraus C, Chu M, Farina E, Fusar Poli P, Marcy PJ, Nunez AR, Calkins ME, Alameda L, Arango C, Borders O, Bouix S, Breitborde NJK, Broome MR, Cadenhead KS, Carrion RE, Castillo-Passi RI, Chen EYH, Choi J, Coleman MJ, Conus P, Corcoran CM, Diaz-Caneja CM, Ellman LM, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui CLM, Kambeitz J, Kambeitz-Ilankovic L, Kapur T, Kelly S, Kerr MJ, Keshavan MS, Kim M, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Lewandowski KE, Mamah D, Mathalon DH, Mittal VA, Mourgues C, Nordentoft M, Pasternak O, Pearlson GD, Penzel N, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Seitz-Holland J, Shah JL, Silverstein SM, Smesny S, Stone WS, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, Yung AR, Zhang T, Addamo L, Buccilli K, Todd S, Dwyer D, Bearden CE, Kane JM, McGorry PD, Kahn RS, Shenton ME, Woods SW, Accelerating Medicines Partnership® Schizophrenia Nelson Barnaby. Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program. Schizophr Bull Open. 2025 Jan; 6(1):sgaf013.
